Electroconvulsive treatment of a patient with Parkinson's disease and moderate depression by Berg, John Erik
[page 8] [Mental Illness 2011; 3:e3]
Mental Illness 2011; volume 3:exxxxElectroconvulsive treatment ofa patient with Parkinson’s dis-ease and moderate depression
John E. Berg Blakstad Hospital, Vestre Viken HospitalTrust, Asker, NorwayFaculty of Health Sciences, OsloUniversity College, Oslo, Norway
Abstract 
Depression is a usual comorbidity in
patients with Parkinson’s disease. It has been
known for more than 50 years that electrocon-
vulsive treatment (ECT) has a positive effect
on the muscular symptoms of Parkinson’s dis-
ease. Many countries do not allow giving ECT
for this indication. We have recently treated a
resident patient in an acute psychiatric facility
referred to the hospital with moderate depres-
sive symptoms and strong suicidal ideation.
Before and after a series of ECT he filled out
the Beck Depression Inventory and the
Antonovsky Sense of Coherence test. The
scores before ECT were 20 and 2.69, respec-
tively, and after 12 treatments 14 and 3.38.
Both test results indicate improvement regard-
ing level of depression and coping in life. The
physiotherapists treating him observed that
his rigidity was reduced and his gait improved.
Muscular tonus was reduced and increased his
tendency of falling as he had less tonus in
muscles close to joints. Self help efficiency in
daily tasks improved. He got cognitive impair-
ment during and in the weeks after ECT.
Electroconvulsive treatment should be offered
to more patients with Parkinson disease and
depression in order to lessen the burden of
both depression and Parkinson symptoms. 
Introduction
Treating depression in a country where
every fifth inhabitant may develop disease dur-
ing their life time, and some risk suicide, is a
challenge.1 Recommendations for treatment
are renewed frequently and now show a shift
from the use of antidepressants prescribed at
the GPs office to cross professional rearrang-
ing of life circumstances in the community.
However, this strategy may not be sufficient
for moderate to severe depressions.2,3
Parkinson’s disease is a life long illness that
heavily influences the daily life of the patient
and the families. The burden on the families is
both emotional and financial.4,5 Some of these
patients live for decades with the illness, and
life is changing substantially. It is well known
that the depression in Parkinson’s disease is
helped by electroconvulsive treatment, but it is
less appreciated that the motor symptoms of
Parkinson is also ameliorated.6,7 Fromm pub-
lished in 1959 the first report on the positive
electroconvulsive treatment (ECT) on
Parkinson’s disease.8 Aarsland et al from
Norway published positive results of mainte-
nance ECT in Parkinson.9 The apathy seen in
patients with Parkinson’s disease may very
well be an expression of undetected depres-
sion.10 Even mania in Parkinson’s disease has
been successfully treated with ECT.11 The pos-
itive effect on motor symptoms may develop
before the effect on the mania using bitempo-
ral stimulation. Delivering ECT is a safe proce-
dure in patients with Parkinson’s disease, as
reported for an old woman with a deep brain
stimulator.12 A 78-year-old woman had suffered
from depression during five years, and her
Parkinson symptoms had deteriorated during
the last two years. She got a deep brain stimu-
lator operated into her left subthalamic nucle-
us. Several antidepressants did not restore her
mood. She then received seven ECTs with
bitemporal stimulation in order to avoid plac-
ing the stimulating electrodes close to the
brain stimulator. The treatment was given with
low energy 201.6 milliCoulomb at 0.9A.
Seizures were observed for more than 33 sec-
onds and recorded as more than 45 seconds on
the EEG of the stimulation apparatus.
Anaesthesia was attained with methohexital
60 mg and succinylcholine 40mg. 
One reason for the restricted use of ECT in
Parkinson’s disease may be the general oppo-
sition against ECT in parts of the population
and among politicians, as shown in a recent
editorial Popeo & Kellner in Medical
Hypothesis.13,14
Parkinson patients may themselves decide
how much dopamine medication they use.
Overdosing dopamine ameliorates depressive
traits, but is followed by side effects that may
be dyskinesias, on-off episodes and more
choreatic movements. There are reports of
confusion, depression, sleep disturbances and
psychotic episodes. We recently treated a
patient with Parkinson’s disease and depres-
sive traits with suicidal ideation. The indica-
tion for treatment with ECT was initially solely
his severe depression. We used several psycho-
metric tests to evaluate the patient before and
after the series ECT. The properties of the
Sense of Coherence test of Antonovsky is
described elsewhere.15-17
Case Report
The patient was 58 years old at referral with
a history of Parkinson’s disease over the last
18 years. The diagnosis of Parkinsons disease
was established at his frequent visits to the
Neurological department of Akershus
University Hospital. He has received Duodopa-
treatment with an external pump for the last
two years. Regular controls took place at the
local neurological policlinic. He lived alone and
most activities of daily life he managed on his
own. Before the present referral he had not
been in contact with psychiatric care or treat-
ment. Half a year before referral his mood
deteriorated. The reason for the referral was
depression and imminent suicidality. A mini
mental status examination at entry was nor-
mal, i.e. no cognitive deficiency. Electro stimulating procedure atBlakstad hospital
Electroconvulsive treatment (ECT) is given
on Monday, Wednesday and Friday every week
of the year. A psychiatrist, a doctor in training
in psychiatry, an anaesthesiologist and a spe-
cially trained nurse are present at the treat-
ment sessions. This is one of several set-ups in
use around the world.18 Nurses from the refer-
ring wards and policlinics accompany the
patients. A treatment course is from 6 to 12
sessions depending on the clinical judgment of
the treating psychiatrist. The treatment is per-
formed in a dedicated room adjacent to the
geronto-psychiatric department using a
Thymatron™ System IV device (Somatics,
LLC, Lake Bluff, IL 60044 USA). Pre-treatment
investigations include general somatic, elec-
trocardiogram, and blood tests and in most
patients a CT scan of the head. A written con-
sent from the patient is compulsory and the
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patient may at any time during the sessions
withdraw his consent. Our clinic monitors two
EEG leads and one for electromyography if
appropriate and also employs a pulse oxymeter.
Stimulation is by right unilateral, bifrontal or
bitemporal electrode placement. Pulse dura-
tion is individually set from 0.25 msec to 1.0
msec and the device is set up to 1008
mCoulomb. Modified treatment is given with
either thiopentalnatrium or propofol followed
by suxametoniumchloride. Atropine is also
given before anaesthesia. The patient is hyper-
ventilated with 100% O2 before the stimula-
tion. Stimulation level follows the age based
method as noted in Petrides & Fink p. 453.19, 20
Treatment procedure and observations in
present case
The patient received 12 sessions of ECT
according to our standard procedure as
described above, see Table 1 for details. He was
stimulated with right unilateral position of the
electrodes, thiopental and suxametoniumchlo-
ride as anaesthesia. 
All sessions gave generalised tonic-clonic
seizures (GTC) observed for more than 15 sec-
onds, which is a threshold for effective GTCs in
some recommendations.21 Post-ictal suppres-
sion of the EEG leads was observed on the tran-
script in all treatment sessions, and the post-
ictal suppression index was > 70%. Visible
motor seizures varied between 22 and 43 sec-
onds. On the EEG the seizures lasted from 20
to 72 seconds, whereas the electromyogram
(EMG) registration varied from 19 to 31 sec-
onds. The stimulus level was increased from
70% to 80% (of 512mCoulomb) after the third
treatment. Seizure threshold usually increases
somewhat during a series of ECTs. After the
eighth treatment the stimulus level was
reduced because of unnecessary lively
seizures increasing the risk of post-ictal mus-
cle pain or fractures, Table 1. 
Results
A marked improvement in mood was
observed after 4-5 treatments. The patient
related more to others and his sentences were
longer and not so cumbersome. His speech was
more comprehensible and involuntary move-
ments were markedly reduced. During the
period with thrice weekly ECT he had problems
remembering appointments and was also con-
fused. Soon after the end of the ECT series he
regained his cognitive capacity. He was
increasingly better able to cope with activities
of daily life and was also good-humoured. Psychometric tests
Beck depression inventory sum-score was
20 before ECT, i.e. a moderate depression.
Sense of Coherence test of Antonovsky mean
score was 2.69 indicating severe problems in
managing, comprehend and cope with life.15,22
After the ECT series both tests were improved.
Beck sum-score was 14 indicating a slight or
mild depression. Sense of Coherence test
mean score was 3,38 indicating better han-
dling and comprehension of life. General
Assessment of Function and Symptoms score
(GAF-F and GAF-S) was before ECT 65 and 60
and after ECT 75 and 78, respectively. Observations by the physiotherapist
The patient got special training with the
hospital staff of physiotherapists almost daily.
He was tested before, during and after the
series of ECTs by the same test procedure. He
would be scored at 4-5 on the Hoehn & Jahr
scale before treatment.23 Involuntary move-
ments and tremor were reduced after 4-5 treat-
ments. Muscular tonus and spasticity in the
extremities were reduced to a score of 2. This
scale does not, however, take the psychic
symptoms into account. There was also a sig-
nificant reduction in annoying muscle cramps
and locking of muscles/joints. He asked for less
pain reducing medication. Cogwheel rigidity
was less prominent after the series of ECT. His
gait improved. He tiptoed less and with fewer
problems initiating movements. On the other
hand, his motoric precision diminished meas-
ured as less finger tapping and supination
movements. His balancing capability and
falling tendency increased. The physiothera-
pists interpreted this after extensive testing as
loss of muscular tonus in muscles close to
joints. The patient was referred from the acute
psychiatry department to a rehabilitation facil-
ity to regain his tonus with his depression at a
sustainable level. 
Discussion
The comorbid condition in the present
patient, depression and Parkinson’s disease,
was much improved by the use of a series of
electroconvulsive treatments. Beck depression
inventory and the Sense of Coherence tests
both corroborate the change, as well as the
impression of the patient. Complete remission
of the depression in such a long-standing case
of Parkinson disease is in our experience not
common. Global functioning improved as
shown by the GAF test. Depression may be a
side effect when treating Parkinson patients
with too much dopamine, but this was not the
case in the present patient. In a comparative
study from the Mayo Clinic it was shown that
the effect on depressive symptoms of ECT was
the same regardless of the patient having
Parkinson’s disease or not.24 Fourteen of 25
patients improved in motoric function, at least
for some time. Controlling for sex and age,
both groups got the same number of treat-
ments. Confusion was more frequent between
treatments among the patients with
Parkinson’s disease. The authors also found
the cognitive status of the patients with
Parkinson’s disease to be decreased before
ECT compared to the control patients. They did
not find a deterioration of cognitive function-
ing in the Parkinson patients. The authors rec-
ommended a small reduction in the dose of lev-
odopa before ECT. This was not done in our
patient after consulting his neurologist. The
observed reduction in cognitive function in our
patient may thus hinge on the fact that we con-
tinued to treat him with the same dose of lev-
odopa. 
Invigorating of the dopamine transmission
and increased sensitivity of dopamine recep-
tors seems to be the mechanism of action of
ECT in Parkinson’s disease.14,24 Zwil & Pelchat
indicated that several neurological diseases
may improve after ECT.25 They pointed out that
rigidity, bradykinesia and on-off phenomena
improved, but that the muscular tremor did not
to the same degree in their patients, somewhat
at odds with our experience. The positive
effects lasted for days or months. Intractable,
medication refractory Parkinson’s disease may
thus be kept in a better state with ECT, where
neurosurgical operations are the only other
option. Improving psychological symptoms
were also observed. The use of ECT in
Parkinson patients without affective disorders
has been studied.26 The mobility in patients
who got real ECT and not sham ECT improved.
Patients with severe disease, high age and
Article
Table 1. Details of registered items at 12 electroconvulsive treatments in a patient with
depression and Parkinson’s disease with Thymatron L 0.5 standard program and thus 0.5
msec pulse width.
Session no. 1 2 3 4 5 6 7 8 9 10 11 12
Stimulus strength 70% 70% 70% 80% 90% 100% 100% 100% 90% 80% 80% 80%
Pulse frequency 50 50 50 60 60 70 70 70 70 70 60 60
Duration of motoric 43 33 36 28 38 35 30 22 27 20 30 28
seizure, seconds
Length of EEG 72 47 37 28 39 37 46 33 35 20 37 46
registered seizures, sec
EMG, sec. 40 31 30 19 28 29 28 16 22 19 26 26
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long standing treatment with levodopa had the
best outcome, as demonstrated in a case of
maintenance ECT in medication refractory ill-
ness from Balke & Varma.27
Continuation and maintenance treatment
with ECT may overcome the shorter duration
of response in many patients with long stand-
ing disease. Resource expenditure with ECT
would be cost effective compared to the other-
wise longer need of resident treatment in hos-
pitals or nursing homes. Even psychotic symp-
toms, which are not uncommon with delusions
and hallucinations, improves after ECT in
Parkinson’s disease.28,29 The probable anti-
Parkinson drug induced psychosis improved
markedly in five elderly patients. 
It is a medico-ethical dilemma that patients
with Parkinson’s disease may not, in many
countries, receive continued ECT after a suc-
cessful treatment series for depression, even
more so because the neurological disease
would improve over time. 
Conclusion
Parkinson disease is often complicated with
depression. Both illnesses improved in the pres-
ent case report after a series of electroconvul-
sive treatments (ECT). He filled out the Beck
Depression Inventory and the Antonovsky
Sense of Coherence test. The scores before ECT
were 20 and 2.69, respectively, and after 12
treatments 14 and 3.38. Both test results indi-
cate improvement regarding level of depression
and coping in life. The physiotherapists treating
him observed that his rigidity was reduced and
his gait improved. Hoehn & Yahr scale score
improved from 5 to 2. Self help efficiency in
daily tasks improved. He got cognitive impair-
ment during and in the weeks after ECT.
Electroconvulsive treatment should be offered
to more patients with Parkinson disease and
depression in order to lessen the burden of both
depression and Parkinson symptoms. 
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